EGFR and non-small cell lung carcinoma: RECEL study was a randomized phase 2 trial comparing erlotinib and etoposide/cisplatin with concurrent radiotherapy for patients with stage IIIA/B unresectable advanced NSCLC with activating EGFR mutation.